Gastroesophageal Reflux Disease (GERD) Clinical Trial
Official title:
Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients With Gastroesophageal Reflux Disease (GERD)
Verified date | December 2007 |
Source | University of Zurich |
Contact | n/a |
Is FDA regulated | No |
Health authority | Switzerland: Swissmedic |
Study type | Interventional |
The primary objective of this study is to investigate whether eradication treatment of
Helicobacter pylori followed by therapy with esomeprazole for a total of 8 weeks extends the
time to relapse in patients with gastroesophageal reflux disease (GERD).
A relapse is defined by two consecutive symptom scores of the Eraflux questionnaire within
14 days that are equal or above the critical value of 25.
The secondary objectives are
1. To compare the time to relapse in the two H. pylori positive study groups with the H.
pylori negative control group
2. To compare the pattern of inflammation and atrophy in the two H. pylori positive
treatment groups with the naturally H. pylori negative control group at relapse.
3. All the above objectives analyzed for the efficacy subset that is the per-protocol
patients broken down by effective H. pylori-eradication.
Secondary endpoints will be analyzed by the following parameters and their interactions:
1. Treatment : Eradicated, Non-eradicated, Hp-negative control
2. Esophagitis at study start: grades 0, A/B and C/D
3. Gender
4. Alcohol intake
5. NSAID/ASA intake (for histological results)
- Trial with medicinal product
Status | Completed |
Enrollment | 0 |
Est. completion date | October 2007 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion criteria: For inclusion in the study the subject must fulfill all of the following criteria: 1. Patients aged between 18 and 70 years. 2. Chronic symptoms (>8 weeks) suggestive for GERD, as defined in Table 2 with or without reflux esophagitis grade A-D (Los Angeles classification) 3. Indication for endoscopy due to GERD symptoms is given 4. Written informed consent Table 2: Lead GERD criteria For inclusion in the study, all of the following lead GERD criteria should hold: - At least one of the symptoms heartburn or regurgitation. - At least 8 weeks ongoing symptoms. - At least 3 times a week. - At least moderate intensity, corresponding to light impairment in daily life and occasional need for drugs. Exclusion criteria: Any of the following is regarded as a criterion for exclusion from the study: 1. Severe organic esophageal disease other than reflux esophagitis (e.g. carcinoma, esophageal stenosis). 2. Gastric or duodenal ulcers 3. Patients with visible Barrett's mucosa; no histological confirmation is required for exclusion 4. History of previous esophageal or gastric surgery 5. Alcohol or drug abuse 6. Severe organic or psychiatric disease 7. Pregnancy or lactation 8. Women with child-bearing potential if no medically accepted contraceptive measures are used 9. Contra-indication to amoxicillin, clarithromycin or esomeprazole (Nexium) 10. Need for concomitant medication which could interfere with the investigational products (substrates of CYP3A4) 11. Suspected or confirmed poor compliance 12. Participation in a clinical study within 8 weeks prior to enrollment. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Switzerland | University Hospital Zurich | Zurich |
Lead Sponsor | Collaborator |
---|---|
University of Zurich | AstraZeneca |
Switzerland,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03561883 -
Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
|
Phase 3 | |
Completed |
NCT02555852 -
Proton Pump Inhibitors and Risk of Community-acquired Pneumonia
|
N/A | |
Completed |
NCT01406210 -
RESULT (REflux Surgery in Lung Transplantation) Preliminary Study Protocol
|
N/A | |
Terminated |
NCT01327963 -
Retrospective TIF Study for Treatment of Gastroesophageal Reflux Disease (GERD). The RetroTIF Study
|
N/A | |
Completed |
NCT01570842 -
Anthropometry in Gastroesophageal Reflux Disease and Esophageal Injury
|
N/A | |
Completed |
NCT02141711 -
TAK-438 - Safety, Blood Levels & Effects of Repeated Doses
|
Phase 1 | |
Terminated |
NCT00587275 -
Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI
|
Phase 2 | |
Completed |
NCT00228527 -
Esomeprazole for Treatment of GERD in Pediatric Patients
|
Phase 4 | |
Completed |
NCT00261300 -
Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints (BY1023/VMG-708)
|
Phase 3 | |
Recruiting |
NCT04506593 -
Indiana University Gastrointestinal Motility Diagnosis Registry
|
||
Completed |
NCT00795093 -
Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US
|
N/A | |
Completed |
NCT00394472 -
Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients
|
Phase 2 | |
Terminated |
NCT02749071 -
An Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Reflux
|
N/A | |
Recruiting |
NCT01129713 -
Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE.
|
Phase 1/Phase 2 | |
Completed |
NCT00734747 -
Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD)
|
Phase 3 | |
Completed |
NCT00312806 -
Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341)
|
Phase 3 | |
Not yet recruiting |
NCT05579587 -
Transoral Incisionless Fundoplication (TIF) for Laryngopharyngeal Reflux (LPR) Patients
|
||
Recruiting |
NCT02366169 -
Medigus Ultrasonic Surgical Endostapler (MUSE) Registry
|
N/A | |
Completed |
NCT01374074 -
Racial Disparity in Barrett's Esophagus
|
N/A | |
Terminated |
NCT00857597 -
Endoscopic Fundoplication Versus Proton Pump Inhibitors for GERD Treatment
|
Phase 3 |